European medicines agency (ema) validates atara biotherapeutics' marketing authorization application for tabelecleucel for the treatment of epstein-barr virus-positive post-transplant lymphoproliferative disease

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the marketing authorization application (maa) for tabelecleucel (tab-cel®) has been fully validated by the european medicines agency (ema). tab-cel is an investigational treatment for patients with epstein-barr virus
ATRA Ratings Summary
ATRA Quant Ranking